ImPrint Biomarker Identifies Breast Cancer Patients Likely to Respond to Immunotherapy

  • 📰 Medscape
  • ⏱ Reading Time:
  • 49 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 44%
  • Publisher: 55%

Health News

Imprint,Biomarker,Breast Cancer

Using ImPrint, an immune-related biomarker, clinicians can identify patients with breast cancer who are likely to respond to neoadjuvant immunotherapy, according to data from the Patient selection based on ImPrint class can result in high response rates and spare nonresponders the toxicities of immunotherapy.

SAN DIEGO — Using ImPrint, an immune-related biomarker, clinicians can identify patients with breast cancer who are likely to respond to neoadjuvant immunotherapy, according to data from the

She added that, although effective, immunotherapy also carries the risk of serious immune-related toxicities, and knowledge of ImPrint class can help patients and physicians determine whether immunotherapy is a good treatment option."Many patients will be willing to take the risk of immunotherapy toxicities if their odds of responding are very high, as is the case for ImPrint+ patients, but likely less enthused with a low likelihood of response," Dr. Wolf said during the interview.

In comparison, pCR rates were only 16% in ImPrint-negative patients. The highest response rate was observed in the anti–PD-1/TLR9 dual immunotherapy arm, with a pCR rate of greater than 90% in ImPrint-positive patients. In the control arm, pCR rates were 33% in ImPrint-positive and 8% in ImPrint-negative patients.

The pCR rates for MP2 and grade III were 56% and 45%, respectively, which are much smaller than the pCR rates observed for ImPrint+ patients .

Source: Healthcare Press (healthcarepress.net)

Imprint Biomarker Breast Cancer Immunotherapy Response Rates Toxicities

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

ImPrint Identifies Treatment for Patients With Breast CancerData from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.
Source: Medscape - 🏆 386. / 55 Read more »

The Wandering Earth II Blu-ray Leads Imprint Asia’s June ReleasesThe epic sci-fi prequel The Wandering Earth II Blu-ray is one of three June releases on the Imprint Asia label.
Source: comingsoonnet - 🏆 578. / 51 Read more »

Martin Scorcese Films of Faith Collection Heads Imprint Films June LineupImprint Films has announced its June releases, which includes the Martin Scorcese Films of Faith limited edition collection.
Source: comingsoonnet - 🏆 578. / 51 Read more »

Olivia Munn’s Breast Cancer Risk Assessment Score 'Saved My Life' — What to Know About the ToolOlivia Munn said she learned of her breast cancer diagnosis after her OB/GYN Dr. Thais Aliabadi calculated her Breast Cancer Risk Assessment Score. The Breast Cancer Risk Assessment Tool is used to estimate a woman’s risk of developing breast cancer within the next five years and within her lifetime.
Source: people - 🏆 712. / 51 Read more »

A new mathematical language for biological networksNew mathematical model of genetic interaction identifies master regulators in biological networks
Source: ScienceDaily - 🏆 452. / 53 Read more »

Navigating the trends shaping the future of DEXs: ReportCointelegraph Research delves into the technological innovations of DEXs and identifies key industry trends.
Source: Cointelegraph - 🏆 562. / 51 Read more »